Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC)— Epidemiology Forecast to 2030

DelveInsight’s ‘EGFR Inhibitors-Induced Skin Disorders- Epidemiology Forecast–2030’ report delivers an in-depth understanding of the EGFR Inhibitors-Induced Skin Disorders historical and forecasted epidemiology in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

EGFR Inhibitors-Induced Skin Disorders Understanding

EGFR Inhibitors-Induced Skin Disorders Overview

The epidermal growth factor receptor (EGFR) is a transmembrane protein that regulates multiple cellular processes. The EGFR inhibitor is a class of targeted antitumor agents designed to bind to the EGFR, thereby preventing its activity. The US FDA, the EMA, and the PMDA have approved several drugs in this class, and associated side effects have also been noticed.

The most common side effects of EGFR-targeted therapies are dermatologic toxicities. EGFR inhibitor-mediated dermatologic side-effects include an acneiform skin rash, hyperpigmentation, xerotic skin, pruritus, skin fissures, nail changes, and disorders of mucous membranes, eyes, and hair.

It is characterized by red papules and/or pustules on the face, chest, abdomen, or thighs; dry and scaly skin; fissures; hyperpigmentation; itchy skin eczema; erythema around several fingernails and toenails and other symptoms observed after anti-EGFR therapy.

EGFR Inhibitors-Induced Skin Disorders Diagnosis

The initial evaluation of a patient with EGFR inhibitors-induced skin disorders includes medical history, physical examination, and clinical symptoms, including the affected area. The lack of clinical practice guidelines for diagnosis and grading is the key unmet need of the EGFR inhibitors-induced skin disorders.

EGFR Inhibitors-Induced Skin Disorders Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Number of Cases on EGFR inhibitors by Cancer Type and Total Cases of EGFR Inhibitors-induced Skin Disorders scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

EGFR Inhibitors-Induced Skin Disorders Detailed Epidemiology Segmentation
• The total number of cases of EGFR Inhibitors-induced Skin Disorders in the 7MM was 106,119 in 2020, which is likely to increase by 2030 at a CAGR of 4.37% for the study period (2018–2030).
• In 2020, the total number of cases of cancer patients on EGFR inhibitors in the US was estimated to be 57,541, which is likely to increase by 2030 at a CAGR of 5.66% for the study period (2018–2030).
• The total number of cases of EGFR Inhibitors-induced Skin Disorders in the US was 37,463 in 2020.
• In 2020, the total number of cancer patients on EGFR inhibitor therapy in the US was highest for NSCLC (28,425), followed by colorectal cancers and breast cancer. Whereas the total cases of EGFR Inhibitors-induced Skin Disorders in the US in 2020 were highest in colorectal cancer (21,453), followed by NSCLC and Head and Neck cancer.
• Among the EU-5 countries, in 2020, the highest cases of EGFR Inhibitors-induced Skin Disorders were found in Germany (12,010), followed by France (9,632) and Italy (9,330); while Spain (7,716) accounted for the least number of cases.
• Japan accounted for 19.89% (21,102 cases) of total cases of EGFR Inhibitors-induced Skin Disorders among 7MM in 2020. These cases are expected to rise by 2030 at a CAGR of 5.12%.

Scope of the Report
• The report covers the descriptive overview of EGFR Inhibitors-Induced Skin Disorders, explaining side effects of EGFR inhibitor treatment, mechanisms underlying EGFR inhibitor-induced cutaneous disorders, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden.
• The report provides the segmentation of the disease epidemiology for 7MM by segmented by Total Number of Cases on EGFR inhibitors by Cancer Type and Total Cases of EGFR Inhibitors-induced Skin Disorders.

Report Highlights
• 10-Year Forecast of EGFR Inhibitors-Induced Skin Disorders
• 7MM Coverage
• Total Number of Cases on EGFR inhibitors by Cancer Type
• Total Cases of EGFR Inhibitors-induced Skin Disorders

Key Questions Answered
• What are the disease risk, burdens, and unmet needs of EGFR Inhibitors-Induced Skin Disorders?
• What is the historical EGFR Inhibitors-Induced Skin Disorders patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of EGFR Inhibitors-Induced Skin Disorders at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to EGFR Inhibitors-Induced Skin Disorders?
• Out of the countries mentioned above, which country would have the highest patient population of EGFR Inhibitors-Induced Skin Disorders during the forecast period (2021–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The EGFR Inhibitors-Induced Skin Disorders report will allow the user to -
• Develop business strategies by understanding the epidemiological trends of EGFR Inhibitors-Induced Skin Disorders in the 7MM.
• Quantify patient populations in the 7MM to improve product design, pricing, and launch plans.
• The EGFR Inhibitors-Induced Skin Disorders epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The EGFR Inhibitors-Induced Skin Disorders epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2018–2030


1. Key Insights
2. Report Introduction
3. EGFR Inhibitors-induced Skin Disorders Epidemiology Overview at a Glance
3.1. Epidemiology Share (%) Distribution of EGFR Inhibitors-induced Skin Disorders in 2018
3.2. Epidemiology Share (%) Distribution of EGFR Inhibitors-induced Skin Disorders in 2030
4. Executive Summary of EGFR Inhibitors-Induced Skin Disorders
5. Disease Background and Overview
5.1. Introduction
5.2. Side Effects of EGFR Inhibitor Treatment
5.3. Mechanisms Underlying EGFR Inhibitors Induced Cutaneous Disorders
5.3.1. Skin inflammation, or rash and folliculitis
5.3.2. Nail and periungual toxicity
5.3.3. Barrier defect/xerosis
5.3.4. Antimicrobial defense/infections
5.3.5. Hair alterations
5.4. Diagnosis
5.4.1. Differential Diagnosis of EGFR-induced rash
5.4.2. Diagnosis and patient education of drug-induced hair disorders
5.4.3. Diagnosis of xerosis cutis
6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Methodology of Epidemiology
6.2.1. NSCLC
6.2.2. Colorectal Cancer
6.2.3. Pancreatic Cancer
6.2.4. Head and Neck Cancer
6.2.5. Breast Cancer
6.3. Total Cases of Cancer on EGFR Inhibitors in the 7MM
6.4. Total Cases on EGFR Inhibitors in the 7MM
6.5. Total Cases of EGFR Induced Skin Disorders in the 7MM
6.6. Total Cases of EGFR Induced Skin Disorders by Cancer Type in the 7MM
6.7. Epidemiology of EGFR Inhibitors-induced Skin Disorders
6.7.1. Assumptions and Rationale for NSCLC
6.7.2. Assumptions and Rationale for Colorectal Cancer
6.7.3. Assumptions and Rationale for Pancreatic Cancer, Breast Cancer, and Head and Neck Cancer
6.8. The United States
6.8.1. Total Number of Cases on EGFR inhibitors by Cancer Type in the US
6.8.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in the US
6.9. EU5
6.9.1. Germany
6.9.1.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Germany
6.9.1.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Germany
6.9.2. France
6.9.2.1. Total Number of Cases on EGFR inhibitors by Cancer Type in France
6.9.2.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in France
6.9.3. Italy
6.9.3.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Italy
6.9.3.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Italy
6.9.4. Spain
6.9.4.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Spain
6.9.4.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Spain
6.9.5. The United Kingdom
6.9.5.1. Total Number of Cases on EGFR inhibitors by Cancer Type in the United Kingdom
6.9.5.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in the United Kingdom
6.10. Japan
6.10.1. Total Number of Cases on EGFR inhibitors by Cancer Type in Japan
6.10.2. Total Cases of EGFR Inhibitors-induced Skin Disorders in Japan
7. Appendix
7.1. Bibliography
7.2. Report Methodology
8. DelveInsight Capabilities
9. Disclaimer
10. About DelveInsight
Table 1 Summary of EGFR Inhibitors-induced Skin Disorders Epidemiology (2018–2030)
Table 2 Summary of the different forms of cutaneous toxicities induced by epidermal growth factor receptor (EGFR)-targeted agents
Table 3 The National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 grading scale (general and specific for acneiform rash)
Table 4 Diagnostic approach to patients with xerosis cutis
Table 5 Total Cases of Cancer on EGFR Inhibitors in the 7MM (2018–2030)
Table 6 Total Cases on EGFR Inhibitors in the 7MM (2018–2030)
Table 7 Total Cases of EGFR Induced Skin Disorders in the 7MM (2018–2030)
Table 8 Total Cases of EGFR Induced Skin Disorders by Cancer Type in the 7MM (2018–2030)
Table 9 EGFR inhibitors for NSCLC
Table 10 Emerging EGFR inhibitors for NSCLC and their expected launch years
Table 11 EGFR inhibitors for NSCLC and their skin disorder-specific adverse events, continued…
Table 12 EGFR inhibitors for NSCLC and their skin disorder-specific adverse events
Table 13 EGFR inhibitors for metastatic colorectal cancer
Table 14 EGFR inhibitors for colorectal cancer and their skin disorder-specific adverse events
Table 15 EGFR inhibitors for Pancreatic, Head and Neck and Breast Cancers
Table 16 EGFR inhibitors for pancreatic cancer and their skin disorder-specific adverse events
Table 17 EGFR inhibitors for head and neck cancer and their skin disorder-specific adverse events
Table 18 EGFR inhibitors for breast cancer and their skin disorder-specific adverse events
Table 19 EGFR inhibitors Patent Expiry
Table 20 Total Number of Cases on EGFR inhibitors by Cancer Type in the United States (2018–2030)
Table 21 Total Cases of EGFR Inhibitors-induced Skin Disorders in the United States (2018–2030)
Table 22 Total Number of Cases on EGFR inhibitors by Cancer Type in Germany (2018–2030)
Table 23 Total Cases of EGFR Inhibitors-induced Skin Disorders in Germany (2018–2030)
Table 24 Total Number of Cases on EGFR inhibitors by Cancer Type in France (2018–2030)
Table 25 Total Cases of EGFR Inhibitors-induced Skin Disorders in France (2018–2030)
Table 26 Total Number of Cases on EGFR inhibitors by Cancer Type in Italy (2018–2030)
Table 27 Total Cases of EGFR Inhibitors-induced Skin Disorders in Italy (2018–2030)
Table 28 Total Number of Cases on EGFR inhibitors by Cancer Type in Spain (2018–2030)
Table 29 Total Cases of EGFR Inhibitors-induced Skin Disorders in Spain (2018–2030)
Table 30 Total Number of Cases on EGFR inhibitors by Cancer Type in the UK (2018–2030)
Table 31 Total Cases of EGFR Inhibitors-induced Skin Disorders in the UK (2018–2030)
Table 32 Total Number of Cases on EGFR inhibitors by Cancer Type in Japan (2018–2030)
Table 33 Total Cases of EGFR Inhibitors-induced Skin Disorders in Japan (2018–2030)
Figure 1 Principles of EGFR activation and inhibition
Figure 2 Mechanism of EGFR inhibitor-induced dermatological toxicity
Figure 3 Schematic representation of potential defects observed in the skin of EGFR inhibitors–treated patients
Figure 4 Total Cases of Cancer on EGFR Inhibitors in the 7MM (2018–2030)
Figure 5 Total Cases on EGFR Inhibitors in the 7MM (2018–2030)
Figure 6 Total Cases of EGFR Induced Skin Disorders in the 7MM (2018–2030)
Figure 7 Total Cases of EGFR Induced Skin Disorders by Cancer Type in the 7MM (2018–2030)
Figure 8 Total Number of Cases on EGFR inhibitors by Cancer Type in the United States (2018–2030)
Figure 9 Total Cases of EGFR Inhibitors-induced Skin Disorders in the United States (2018–2030)
Figure 10 Total Number of Cases on EGFR inhibitors by Cancer Type in Germany (2018–2030)
Figure 11 Total Cases of EGFR Inhibitors-induced Skin Disorders in Germany (2018–2030)
Figure 12 Total Number of Cases on EGFR inhibitors by Cancer Type in France (2018–2030)
Figure 13 Total Cases of EGFR Inhibitors-induced Skin Disorders in France (2018–2030)
Figure 14 Total Number of Cases on EGFR inhibitors by Cancer Type in Italy (2018–2030)
Figure 15 Total Cases of EGFR Inhibitors-induced Skin Disorders in Italy (2018–2030)
Figure 16 Total Number of Cases on EGFR inhibitors by Cancer Type in Spain (2018–2030)
Figure 17 Total Cases of EGFR Inhibitors-induced Skin Disorders in Spain (2018–2030)
Figure 18 Total Number of Cases on EGFR inhibitors by Cancer Type in the United Kingdom (2018–2030)
Figure 19 Total Cases of EGFR Inhibitors-induced Skin Disorders in the United Kingdom (2018–2030)
Figure 20 Total Number of Cases on EGFR inhibitors by Cancer Type in Japan (2018–2030)
Figure 21 Total Cases of EGFR Inhibitors-induced Skin Disorders in Japan (2018–2030)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook